The UK-US deal does not resolve every challenge – no single agreement could. But it marks a meaningful step toward restoring ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Singaporean Health Sciences Authority (HSA) say the ...

Drug delivery is no longer just about convenience. It’s about enabling the therapies of the future to succeed where they ...

RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series ...

A court in Munich has granted a preliminary injunction that will prevent MSD from distributing the subcutaneous version of its cancer immunotherapy Keytruda in the German market. The verdict is the ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth. Pharma’s ...

Netherlands-based argenx has published positive topline results from its ADAPT SERON trial of its market-leading drug for generalised myasthenia gravis (gMG) Vyvgart (efgartigimod). Significantly, the ...

Hundreds of people with a rare and aggressive form of leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after it was recommended for routine commissioning by the NHS.

AstraZeneca's baxdrostat has hit the mark in another phase 3 trial involving people who struggle to control their blood pressure with current therapies, keeping the would-be blockbuster on track for ...